Shaoxing City Youluofei Pharmaceutical Co. Ltd. has identified adenosine receptor ligands reported to be useful for the treatment of cancer, diabetes, pain, neuroinflammation, metabolic diseases, cardiovascular diseases, respiratory disorders and inflammatory disorders, among others.
Two in five preclinical studies on subarachnoid hemorrhage (SAH) published in peer-reviewed scientific journals contain problematic images. A team of researchers from Radboud University Medical Center, who had previously identified several such cases, analyzed the literature in this field to assess the scope of the issue. They found that 40% of the studies included suspicious images.
Ascletis Pharma Inc. has selected ASC-36, a once-monthly, potentially best-in-class subcutaneously administered amylin receptor peptide agonist, as a clinical development candidate.
Corsera Health Inc. has filed a clinical trial notification (CTN) seeking to initiate a phase I trial of COR-1004 in New Zealand. COR-1004 is a novel investigational subcutaneously administered siRNA targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) to reduce LDL cholesterol (LDL-C).
Myocardial ischemia-reperfusion (MI/R) injury is a major contributor to heart failure. The long noncoding RNA (lncRNA) myocardial infarction-associated transcript (MIAT) has been shown to worsen cardiac damage during ischemia, making it a promising target for RNA interference.
Septic cardiomyopathy is a common and serious complication of sepsis, affecting up to 60% of patients and markedly worsening survival outcomes. It is characterized by left ventricular systolic dysfunction, but its underlying mechanisms remain poorly understood despite extensive research.
Corventum Inc. has gained IND clearance from the FDA for CVT-130 for the prevention of anthracycline-related cardiotoxicity. In cancer patients, the use of anthracyclines as chemotherapy is effective but limited by cumulative heart damage. Protecting against this chemotherapy-induced cardiac injury could enable retreatment for patients with recurrent cancer.
A preclinical study presented at the 32nd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), held in Seville Oct. 7-10, showed a new epigenetic editing technology that enables durable gene silencing using ELXRs, short for Epigenetic Long-Term X-Repressors. With this approach, scientists at Scribe Therapeutics Inc. successfully inhibited the expression of the PCSK9 gene, a key regulator of cholesterol metabolism, in human cells, mice and nonhuman primates.
When the levels of LDL cholesterol are elevated, there is increased risk for atherosclerotic cardiovascular disease. Lowering these levels contributes to decreasing the risk of major adverse cardiovascular events. EDIT-401 is a CRISPR-based LDL cholesterol-lowering gene-editing approach developed by Editas Medicine Inc.
RSS
